This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year postcommercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, our analysis assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. Our content provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other agents for multiple myeloma.

Table of contents

  • Darzalex/Empliciti Launch Tracking Wave 2 (US)
    • Key Findings
    • Benchmarking Darzalex and Empliciti Launch Success Versus the Competition
      • Darzalex and Empliciti Compare Well Against Benchmarks
    • Prescriber and Nonprescriber Profiles
      • Differences Between Darzalex and Empliciti Prescribers and Nonprescribers
    • Darzalex and Empliciti Awareness and Perceptions
      • Unaided and Aided Awareness of Darzalex and Empliciti
      • Familiarity with Darzalex and Empliciti
      • Sources of Familiarity with Darzalex and Empliciti
      • Initial Reactions to and Interest in Darzalex and Empliciti
      • Impressions of Darzalex and Empliciti
    • Darzalex and Empliciti Trial and Use
      • Willingness to Prescribe Darzalex and Empliciti
        • Enthusiasm Is High for Darzalex and Empliciti
      • Number of Patients Now Receiving Darzalex and Empliciti
        • Two-Thirds of Respondents Are Now Darzalex and/or Empliciti Prescribers
      • Reasons for Not Yet Prescribing Darzalex and Empliciti
        • Caution and Cost-Effectiveness Concerns Prevail
      • Anticipated Darzalex and Empliciti Use
        • Insurance Plan Treatment Duration Restrictions Relaxed
      • Darzalex and Empliciti Performance on Key Attributes
        • Satisfaction Levels Remain High
    • Effectiveness of Face-to-Face Detailing for Darzalex and Empliciti
      • Darzalex and Empliciti Sales Representative Frequency and Reach
        • Call Frequency Rates Are Maintained for Darzalex but Falter for Empliciti
      • Satisfaction with Darzalex and Empliciti Sales Representatives
        • Darzalex and Empliciti Sales Representatives Are Highly Regarded by Prescribers
      • Darzalex and Empliciti Message Recall
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • List of Abbreviatons
      • Additional Information
        • Screening Questions
        • Awareness of Drugs for Multiple Myeloma Treatment
        • Patient Profile of Off-label Prescriptions
        • Barriers to Prescribing Darzalex and Empliciti
        • Impact on Prescription of Other Agents Since the Commercial Availability of Darzalex and Empliciti
        • Coordinated Dosing Schedules of Darzalex and/or Empliciti to Minimize Drug Wastage
        • Influence of Managed Care Approval Process on Darzalex and/or Empliciti Prescriptions
        • Patient Awareness of Darzalex and Empliciti
        • Prescription Preference for Multiple Myeloma Patients
        • Case Study #1: ASCT-Ineligible Multiple Myeloma Patient Previously Prescribed Velcade + Dexamethasone (BD)
        • Case Study #2: Patient with Multiple Myeloma Quickly Progressed to Fourth Line of Therapy
        • Performance of Sales Representatives
        • Willingness for Follow Up Interview

Author(s): Izabela Ammermann, PhD; Dana Gheorghe

Izabela Ammermann, , is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a in molecular biology from the Technical University of Munich and a in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.

Related Reports

Multiple Myeloma | Geographic Focus: China | Multiple Myeloma | China In-Depth | China

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the intro...

View Details

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet...

View Details

Multiple Myeloma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapi...

View Details

Multiple Myeloma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of mu...

View Details